Neurocrine Biosciences | NBIX - Interest Expense On Debt



Neurocrine Biosciences reported $1.1M in Interest Expense on Debt for its fiscal quarter ending in March of 2024.


Interest Expense On Debt Change Date
AbbVie USD 700M 90M Mar/2025
Acadia Pharmaceuticals 0 4.12M Sep/2024
Agios Pharmaceuticals 3.01M 10.05M Dec/2024
ALKERMES USD 0 0 Jun/2025
Alnylam Pharmaceuticals USD 40.25M 1.6M Jun/2025
Amgen USD 694M 29M Jun/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.68M 184K Jun/2025
Cytokinetics USD 24.26M 1.32M Jun/2025
Dynavax Technologies USD 1.64M 51K Jun/2025
Exelixis 23.4M 3.9M Sep/2023
Gilead Sciences USD 254M 6M Jun/2025
Halozyme Therapeutics USD 4.39M 131K Jun/2025
Incyte USD 594K 66K Jun/2025
Ionis Pharmaceuticals USD 19M 0 Jun/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Pfizer USD 654M 0 Jun/2025
Prothena 0 0 Jun/2024
Regeneron Pharmaceuticals USD 3.6M 5.1M Jun/2025
Repligen USD 5.35M 104K Jun/2025
Sarepta Therapeutics USD 5.23M 725K Jun/2025
Teva Pharmaceutical Industries USD 252M 40M Jun/2025
Ultragenyx Pharmaceutical 14.04M 1.48M Jun/2025
Vertex Pharmaceuticals USD 3.7M 900K Jun/2025